Overview of Glp 1 Analogs Tusom Pharmwiki

GLP-1 Analogs When choosing a GLP-1 receptor agonist, options include long-acting vs short-acting agents, the need for reconstitution, patient preference, health insurance coverage & cost to the patient. Injection procedures are more complicated with once-weekly medications.

The discovery of DPP-IV-resitant GLP-1 analogs was pursued in parallel with the discovery of DPP-IV inhibitors. Exenatide is a synthetic form of a protein originally isolated from the saliva of the Gila monster (poisonous lizard that lives in the deserts of Arizona) (Triplitt & Chiquette, 2003).
updatestoendocrinepharm TUSOM

Updated the indications section for DPP-4 inhibitors & GLP-1 analogs regarding use with insulin. Minor update on the indication for pramlintide - it is FDA approved as a drug to be combined with insulin The section on sulfonylureas and glitinides has been updated for accuracy & completeness. The hypoglycemics summary tables was revised & updated.
Clinical trials indicate that DPP-4 inhibitors produce no change in weight, in contrast to GLP-1 agonists, such as exenatide, which produce moderate weight loss which has been attributed to the ~5x stronger "incretin mimetic" effect produced by GLP-1 analogs compared to DPP-4 inhibitors (Charbonnel & Cariou, 2011) Figure 6.

endocrinepharm TUSOM
Oral GLP-1 Agonists Semaglutide (Rybelsus ®) Orforglipron (phase 2 trials; not available)
Mechanism of Action: A GIP 1 ) analog & GLP-1 receptor agonist hypoglycemic peptide analog of GIP containing an attached C 20 fatty diacid to optimize uptake (80% BA) and metabolism, and prolong its half-life (t 1/2 : 5 days), and by enhancing its affinity for albumin (99% is bound at therapeutic levels) Indications: Mounjaro:

start TUSOM
The PharmWiki is intended to be a student-centered "one stop shopping" learning resource for: up-to-date drug information (e.g. mechanisms, indications, side effects, drug interactions) links to additional information resources (not everything can be found in a wiki)
GLP-1 analogs are molecules that are structurally almost identical to the endogenous GLP-1 hormone. Incretin mimetics are substances that mimic the actions of incretin hormones such as GLP-1 and GIP. Originally developed to treat type 2 diabetes, some GLP-1 agonists have been approved to treat obesity.

jm500810s 1.
In this Perspective, we focus on GLP-1 analogs for their studies on improvement of biological activities, enhancement of metabolic stability, investigation of receptor interaction, and visualization of the pancreatic islets.




Abstract Glucagon-like peptide-1 ( GLP-1 ), secreted by L cells in the small intestine, assumes a central role in managing type 2 diabetes mellitus (T2DM) and obesity. Its influence on insulin secretion and gastric emptying positions it as a therapeutic linchpin.